Association between apolipoprotein E genotype and warfarin response during initial anticoagulation

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Shuai HeXin Chen

Abstract

Apolipoprotein E (APOE) genotypes are associated with warfarin dose requirements in various populations. Whether APOE genotypes mediate the warfarin response is unknown. The aim of this study was to evaluate the genetic contributions of different APOE genotypes to the early phase of anticoagulation in Han Chinese patients. We conducted a retrospective cohort study and assessed APOE genotypes, clinical characteristics, international normalized ratio (INR) responses, warfarin dose requirements and bleeding events in 429 Han Chinese patients. The study outcomes were the time to the first INR within the therapeutic range, the time to the first INR of more than 4, the INR response over time, and the warfarin dose requirement. Compared with patients with the ε3/ε3 genotype, patients with at least one ε4 allele had significantly longer times to the first INR of more than 4 during both the initial 20 days (P = 0.001, HR 2.9; 95%CI, 1.54-5.45) and the entire follow-up period (P < 0.001, HR 3.26; 95%CI,1.94-5.47), but this allele was not a significant predictor of the time to the first INR within the therapeutic range. No association was observed between the ε2 allele and INR response, and both the ε4 allele and the ε2 allele did not sig...Continue Reading

References

Dec 1, 1987·The Journal of Clinical Investigation·M S WeintraubJ L Breslow
Apr 1, 1996·The Journal of Nutrition·M KohlmeierM J Shearer
Jan 1, 1997·Pharmacology & Therapeutics·L S Kaminsky, Z Y Zhang
Nov 20, 1998·Chest·M N LevineC Kearon
Apr 3, 2002·JAMA : the Journal of the American Medical Association·Mitchell K HigashiAllan E Rettie
Aug 15, 2003·The New England Journal of Medicine·Clive KearonUNKNOWN Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators
Feb 7, 2004·Nature·Tao LiDarrel W Stafford
Mar 6, 2004·Clinical Pharmacology and Therapeutics·Farhad KamaliHilary Wynne
Apr 30, 2005·Pharmacogenetics and Genomics·Loes E VisserBruno H Ch Stricker
Jun 3, 2005·The New England Journal of Medicine·Mark J RiederAllan E Rettie
Jun 14, 2005·European Journal of Clinical Pharmacology·Hugo KohnkeMia Wadelius
Sep 1, 2005·European Journal of Clinical Pharmacology·Hugo KohnkeMia Wadelius
Jul 6, 2006·Trends in Biochemical Sciences·Danny M HattersKarl H Weisgraber
Jul 19, 2006·Pharmacogenetics and Genomics·Elizabeth A SconceFarhad Kamali
Oct 19, 2006·Human Genetics·Mia WadeliusPanos Deloukas
Feb 28, 2007·The Pharmacogenomics Journal·S E KimmelA S Whitehead
Sep 20, 2007·JAMA : the Journal of the American Medical Association·Anna M BennetJohn Danesh
Nov 9, 2007·Circulation·Jeffrey L AndersonUNKNOWN Couma-Gen Investigators
Nov 13, 2007·British Journal of Clinical Pharmacology·Suman LalBalram Chowbay
Mar 7, 2008·The New England Journal of Medicine·Ute I SchwarzC Michael Stein
Feb 20, 2009·Journal of the American Society of Nephrology : JASN·Nita A LimdiMichael Allon
Feb 21, 2009·The New England Journal of Medicine·UNKNOWN International Warfarin Pharmacogenetics ConsortiumJ A Johnson
Jan 15, 2010·Clinical Pharmacology and Therapeutics·L H CavallariJ A Johnson
Apr 21, 2010·Pharmacogenomics·Guang-Ming TanBryan P Yan
Nov 21, 2013·The New England Journal of Medicine·Stephen E KimmelUNKNOWN COAG Investigators

❮ Previous
Next ❯

Citations

Oct 2, 2021·European Journal of Clinical Pharmacology·Xiaotong XiaJinhua Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.